These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 34256669)
1. Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries. Conaghan PG; Keininger DL; Holdsworth EA; Booth N; Modi NN; Tian H; Kiltz U Curr Med Res Opin; 2021 Oct; 37(10):1845-1853. PubMed ID: 34256669 [TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis. Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab. Magrey M; Bozyczko M; Wolin D; Mordin M; McLeod L; Davenport E; Chirila C; Hur P Clin Drug Investig; 2019 Dec; 39(12):1205-1212. PubMed ID: 31549346 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716 [TBL] [Abstract][Full Text] [Related]
5. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070 [TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. Gandjour A; Ostwald DA Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482 [TBL] [Abstract][Full Text] [Related]
7. Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. Orbai AM; McInnes IB; Coates LC; Husni ME; Gladman DD; Gossec L; Pricop L; Chambenoit O; Meng X; Mease PJ J Rheumatol; 2020 Jun; 47(6):854-864. PubMed ID: 31615919 [TBL] [Abstract][Full Text] [Related]
8. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531 [TBL] [Abstract][Full Text] [Related]
9. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Furst DE; Tran M; Sullivan E; Pike J; Piercy J; Herrera V; Palmer JB Clin Rheumatol; 2017 Sep; 36(9):2045-2054. PubMed ID: 28238086 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R; RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143 [TBL] [Abstract][Full Text] [Related]
12. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study. Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Galán-Gutierrez M; Armario-HIta JC; Martinez-Pilar L Int J Dermatol; 2020 May; 59(5):633-639. PubMed ID: 32173862 [TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis. Alegre-Sancho JJ; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; Pedraz-Penalva T; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martinez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Sivera F Front Med (Lausanne); 2023; 10():1294247. PubMed ID: 38053615 [TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective. Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Molica Colella F; Zizzo G; Parrino V; Filosa MT; Cavaliere R; Fazio F; Molica Colella AB; Mazzone A Adv Rheumatol; 2023 Mar; 63(1):15. PubMed ID: 36973825 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab. Furer V; Zisman D; Kaufman I; Arad U; Berman M; Sarbagil-Maman H; Elias M; Hadad A; Paran D; Drori Y; Friedman N; Mandelboim M; Elkayam O Vaccine; 2020 Jan; 38(4):847-851. PubMed ID: 31767465 [TBL] [Abstract][Full Text] [Related]
17. Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study. Joven B; Manteca CF; Rubio E; Raya E; Pérez A; Hernández R; Manrique S; Núñez M; Díaz-Cerezo S; Moyano S; Lacetera A; García-Vicuña R Adv Ther; 2023 Dec; 40(12):5415-5431. PubMed ID: 37804475 [TBL] [Abstract][Full Text] [Related]
18. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study. Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743 [TBL] [Abstract][Full Text] [Related]
19. Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network. Gladman DD; Choquette D; Khraishi M; Inman RD; Hussein S; Neish D; Leclerc P J Rheumatol; 2023 May; 50(5):641-648. PubMed ID: 36521913 [TBL] [Abstract][Full Text] [Related]
20. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]